Astrazeneca Plc $AZN is Trillium Asset Management LLC’s 5th Largest Position

Trillium Asset Management LLC decreased its position in Astrazeneca Plc (NYSE:AZN) by 16.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 481,980 shares of the company’s stock after selling 93,938 shares during the period. Astrazeneca comprises 2.6% of Trillium Asset Management LLC’s investment portfolio, making the stock its 5th biggest position. Trillium Asset Management LLC’s holdings in Astrazeneca were worth $84,587,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AZN. Brighton Jones LLC increased its holdings in Astrazeneca by 93.2% in the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company’s stock valued at $379,000 after buying an additional 2,789 shares in the last quarter. AQR Capital Management LLC increased its stake in shares of Astrazeneca by 45.3% during the first quarter. AQR Capital Management LLC now owns 37,501 shares of the company’s stock worth $2,756,000 after purchasing an additional 11,690 shares in the last quarter. Amundi increased its stake in shares of Astrazeneca by 54.4% during the second quarter. Amundi now owns 10,274 shares of the company’s stock worth $731,000 after purchasing an additional 3,618 shares in the last quarter. Jump Financial LLC increased its stake in shares of Astrazeneca by 898.4% during the second quarter. Jump Financial LLC now owns 33,478 shares of the company’s stock worth $2,339,000 after purchasing an additional 30,125 shares in the last quarter. Finally, Daiwa Securities Group Inc. increased its stake in shares of Astrazeneca by 1.2% during the second quarter. Daiwa Securities Group Inc. now owns 46,642 shares of the company’s stock worth $3,259,000 after purchasing an additional 559 shares in the last quarter. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Astrazeneca Stock Performance

NYSE:AZN opened at $178.79 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.91 and a quick ratio of 0.71. The firm has a market capitalization of $277.28 billion, a price-to-earnings ratio of 26.85, a PEG ratio of 1.59 and a beta of 0.25. The company’s 50-day moving average is $189.26 and its two-hundred day moving average is $185.90. Astrazeneca Plc has a 1-year low of $137.23 and a 1-year high of $212.71.

Astrazeneca (NYSE:AZN) last posted its earnings results on Wednesday, April 29th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. Analysts forecast that Astrazeneca Plc will post 9.37 EPS for the current year.

Analyst Ratings Changes

AZN has been the subject of a number of research reports. JPMorgan Chase & Co. reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday. DZ Bank raised shares of Astrazeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 29th. Barclays reissued a “buy” rating on shares of Astrazeneca in a research note on Monday, June 1st. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Astrazeneca in a research note on Tuesday. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Astrazeneca in a research note on Tuesday. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Astrazeneca currently has a consensus rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Company Profile

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.